{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:56Z","timestamp":1792789796063,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea, Oradea, Romania","id":[{"id":"https:\/\/ror.org\/00wzhv093","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/00wzhv093","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This exploratory single-center retrospective cross-sectional study characterized patients with documented diabetic peripheral neuropathy (DPN) according to documented GLP-1-based medication status. GLP-1-based medication status was defined by a hospital medication-field entry for exenatide, dulaglutide, semaglutide, a fixed-ratio insulin\/GLP-1 receptor agonist combination, or tirzepatide, a dual GIP\/GLP-1 receptor agonist. Materials and Methods: Medication-level records from a hospital-defined February 2024\u2013February 2026 reporting window were aggregated by PatID for 4120 unique patients in active-patient exports from the Clinical County Emergency Hospital Bihor. The files lacked patient-level encounter, diagnosis, and treatment dates; therefore, they were analyzed as an undated reporting snapshot. DPN and diabetes type were defined from export fields and were not independently clinically validated. Results: GLP-1-based medications were documented in 852 patients (20.7%). Patients with these medications in their records had longer documented diabetes duration (14.85 \u00b1 8.64 vs. 11.72 \u00b1 8.73 years; p &lt; 0.001) and a higher documented comorbidity count (2.64 \u00b1 1.65 vs. 1.89 \u00b1 1.55; p &lt; 0.001). Heart failure was documented in 35.7% versus 22.2%, and any lower-limb amputation in 3.3% versus 1.2%. For heart failure, the adjusted odds ratio was 1.68 (95% CI 1.41\u20131.99) in the primary model and 1.37 (1.12\u20131.67) in the expanded exploratory model; the corresponding robust Poisson prevalence ratio was 1.45 (1.30\u20131.63). Because only 66 amputations were recorded, amputation was retained as a descriptive, unadjusted outcome and was not modeled multivariably. Conclusions: A GLP-1-based medication record identified a clinically complex subgroup with documented DPN. The findings are exploratory and hypothesis-generating; because treatment and outcome dates were unavailable, they do not establish temporality, treatment benefit, or treatment harm.<\/jats:p>","DOI":"10.3390\/medicina62091816","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:25:43Z","timestamp":1789986343000},"page":"1816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study"],"prefix":"10.3390","volume":"62","author":[{"given":"Anca Cristina","family":"Ferician","sequence":"first","affiliation":[{"name":"Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410068 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-1958","authenticated-orcid":false,"given":"Timea Claudia","family":"Ghitea","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela Simona","family":"Popoviciu","sequence":"additional","affiliation":[{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic Neuropathy: A Position Statement by the American Diabetes Association","volume":"40","author":"Boulton","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic Foot Ulcers and Their Recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024","volume":"47","author":"Draznin","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e16242","DOI":"10.1111\/jnc.16242","article-title":"Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis","volume":"169","author":"Fan","year":"2024","journal-title":"J. Neurochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20420986231178126","DOI":"10.1177\/20420986231178126","article-title":"Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: A meta-analysis of 2 million patients","volume":"14","author":"Lu","year":"2023","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jama.2010.1205","article-title":"Minimizing bias due to confounding by indication in comparative effectiveness research: The importance of restriction","volume":"304","author":"Psaty","year":"2010","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ije\/dyp334","article-title":"Illustrating bias due to conditioning on a collider","volume":"39","author":"Cole","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Barros, A.J.D., and Hirakata, V.N. (2003). Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med. Res. Methodol., 3.","DOI":"10.1186\/1471-2288-3-21"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: Results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., G\u00f8tzsche, P.C., Vandenbroucke, J.P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., S\u00f8rensen, H.T., von Elm, E., and Langan, S.M. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001885"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhu, J., Hu, Z., Luo, Y., Liu, Y., Luo, W., Du, X., Luo, Z., Hu, J., and Peng, S. (2023). Diabetic peripheral neuropathy: Pathogenetic mechanisms and treatment. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1265372"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","article-title":"Effects of GLP-1 receptor agonists on neurological complications of diabetes","volume":"24","author":"Ariza","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-025-02175-1","article-title":"Diabetic neuropathy: Cutting-edge research and future directions","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00125-024-06099-3","article-title":"Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"67","author":"Cardoso","year":"2024","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, Y., Chen, J., Zhang, S., Zhu, D., Deng, F., Zuo, R., Hu, Y., Zhao, Y., Duan, Y., and Lin, B. (2024). Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on time in range in patients with type 2 diabetes. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1370594"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s13300-021-01116-9","article-title":"Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review","volume":"12","author":"Fernando","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1111\/dom.70523","article-title":"Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study","volume":"28","author":"Maier","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-018-0781-1","article-title":"Lower extremity arterial disease in patients with diabetes: A contemporary narrative review","volume":"17","author":"Nativel","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gong, H., Ren, Y., Li, Z., Zha, P., Bista, R., Li, Y., Chen, D., Gao, Y., Chen, L., and Ran, X. (2023). Clinical characteristics and risk factors of lower extremity amputation in diabetic inpatients with foot ulcers. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1144806"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112982","DOI":"10.1016\/j.diabres.2025.112982","article-title":"Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease","volume":"230","author":"Hong","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.1038\/s41598-024-65495-2","article-title":"Prevalence of peripheral neuropathy, amputation, and quality of life in patients with diabetes mellitus","volume":"14","author":"Perveen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Caruso, P., Di Martino, N., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M.I., Esposito, K., and Giugliano, D. (2026). Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of RCTs and cohort studies. Cardiovasc. Diabetol., Epub ahead of printing.","DOI":"10.1186\/s12933-026-03283-0"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1816\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:29:27Z","timestamp":1789990167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091816"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091816","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}